Brainstorm Cell Therapeutics Inc. (Brainstorm) is a development-stage company. The Company is engaged in developing stem cell therapeutic products based on technologies enabling the in-vitro differentiation of bone marrow stem cells to neural-like cells. The Company focuses on utilizing the patient’s own bone marrow stem cells to generate neurotrophic factors (NTF) cells that may provide treatment for amyotrophic lateral sclerosis (ALS), parkinson’s disease (PD) and spinal cord injury. The Company’s technology is based on the NurOwn products, an autologous cell therapeutic modality, consisting of the extraction of the patient bone marrow, processed into neuronal-like cells and re-implanted into the patient’s muscles or brain.